Urothelial Cancer Survival in the Eras Before and After Immune Checkpoint Inhibitors and Antibody-Drug Conjugates

“Our data allow clinicians and researchers to characterize the contemporary survival benefits of immune checkpoint inhibitors and antibody-drug conjugates for patients in routine care and may be used to benchmark outcomes from future clinical trials.”

CRISPR-Cas9–Edited Tumor-Infiltrating Lymphocytes in Metastatic Colorectal Cancer

In a first-in-human, single-institution phase I trial reported in The Lancet Oncology, Lou et al found that autologous tumor-infiltrating lymphocytes genetically edited with CRISPR-Cas9 to target the intracellular immune checkpoint CISH were tolerable and showed evidence of activity in patients with metastatic colorectal cancer. These lymphocytes are edited to enable knockout of CISH, which encodes a novel intracellular immune checkpoint target.

Thyroidectomy Without Postoperative Radioiodine Ablation in Low-Risk Differentiated Thyroid Cancer

The phase III IoN trial compared survival outcomes among patients with low-risk differentiated thyroid cancer who underwent thyroidectomy with no postoperative radioiodine ablation vs thyroidectomy plus ablation.